Mounjaro vs Ozempic: How Two Weekly Diabetes Medicines Differ

    Short answer

    Mounjaro (tirzepatide, Eli Lilly) acts on GIP and GLP-1 receptors; Ozempic (semaglutide, Novo Nordisk) acts on GLP-1 receptors. Both are once-weekly injections for adults with type 2 diabetes. In the SURPASS-2 trial on the Mounjaro label, average HbA1c and weight fell more on each Mounjaro dose than on semaglutide 1 mg.

    Mounjaro contains tirzepatide and is made by Eli Lilly, while Ozempic contains semaglutide and is made by Novo Nordisk. Both are once-weekly injections approved for adults with type 2 diabetes, and Ozempic also has a daily tablet on a separate label. Below, the Mounjaro label (revised 08/2026), the Ozempic injection label (revised 05/2026) and the Ozempic tablets label (revised 01/2026) sit side by side, including the one head-to-head trial printed on the Mounjaro label. The choice between them is a conversation for you and your prescriber, not a verdict from this guide.

    The Short Answer

    One Pathway or Two

    Ozempic acts on one hormone receptor, GLP-1. Mounjaro acts on two, GIP and GLP-1, as its label describes it.

    Both Are for Type 2 Diabetes

    Both labels cover blood sugar control in adults with type 2 diabetes and lowering heart event risk in certain adults with diabetes. Neither label lists weight reduction as an approved use.

    A Head-to-Head Trial Exists

    The Mounjaro label includes SURPASS-2, a 40-week trial against semaglutide 1 mg in adults with type 2 diabetes. Average HbA1c and body weight fell more on Mounjaro, and the details are below.

    Stomach Effects Lead Both Lists

    Nausea, diarrhea, vomiting and constipation are common on both labels. They tend to show up while the dose is being raised.

    Mounjaro and Ozempic at a Glance

    One row per label fact, from the Mounjaro, Ozempic and Ozempic tablets prescribing information.

    MounjaroOzempic
    IngredientTirzepatideSemaglutide
    MakerEli LillyNovo Nordisk
    ReceptorsGIP and GLP-1GLP-1
    Approved usesType 2 diabetes (adults and children 10+); heart event risk reduction in high-risk adultsType 2 diabetes in adults; heart and kidney risk reduction in some of those adults
    FormsWeekly injection: single-dose pen or vial, multi-dose vial or KwikPenWeekly injection (pen or prefilled syringe); daily tablet on a separate label
    Injection sitesStomach area, thigh; back of the upper arm if someone else injectsStomach area, thigh, upper arm

    Approved Uses in Full

    Mounjaro is approved for blood sugar control in adults and in children 10 and older with type 2 diabetes. It is also approved to lower major heart event risk in adults with type 2 diabetes who are at high risk for these events.

    Ozempic is approved for blood sugar control in adults with type 2 diabetes. Its label also covers lowering heart event risk in those adults with heart disease and lowering kidney decline risk in those with chronic kidney disease.

    Forms and How Often

    Both injections are taken once a week at any time of day, with or without meals. Mounjaro comes in single-dose pens, single-dose vials, multi-dose vials or a multi-dose KwikPen, while Ozempic injection comes in a multi-dose pen or a single-dose prefilled syringe.

    Ozempic tablets are taken once a day on an empty stomach with up to 4 ounces of water, on a label shared with Rybelsus. Mounjaro has no tablet form.

    Where the Shot Goes

    Both labels list the stomach area and the thigh as injection sites, and both say to rotate sites with each dose. Ozempic adds the upper arm, and the Mounjaro label says another person can inject in the back of the upper arm. More in GLP-1 injection sites.

    Their Weight-Focused Siblings

    Tirzepatide is also sold as Zepbound, and semaglutide is also sold as Wegovy, each with its own label for weight reduction. The Wegovy vs Zepbound comparison covers those two.

    Who Should Not Use Either One

    Both labels rule out anyone with a personal or family history of medullary thyroid carcinoma or with MEN 2. Both also rule out a known serious allergy to the active ingredient or other ingredients.

    What the SURPASS-2 Trial Found

    SURPASS-2 is the published head-to-head trial, printed in Table 5 of the Mounjaro label. Every figure is a group average from one open-label trial at 40 weeks.

    Trial armAverage HbA1c changeAverage weight change
    Mounjaro 5 mg-2.0 points-7.6 kg
    Mounjaro 10 mg-2.2 points-9.3 kg
    Mounjaro 15 mg-2.3 points-11.2 kg
    Semaglutide 1 mg-1.9 points-5.7 kg

    How the Trial Was Set Up

    SURPASS-2 randomized 1,879 adults with type 2 diabetes already taking metformin to Mounjaro 5 mg, 10 mg or 15 mg, or semaglutide 1 mg, once weekly for 40 weeks. It was open-label and funded by Eli Lilly, and the results are printed in Table 5 of the Mounjaro label.

    HbA1c Results

    Average HbA1c fell by 2.0, 2.2 and 2.3 points on the three Mounjaro doses, compared with 1.9 points on semaglutide 1 mg. The label reports all three Mounjaro doses (5, 10 and 15 mg) as statistically superior to semaglutide 1 mg for HbA1c.

    Body Weight Results

    Average weight fell by 7.6 kg, 9.3 kg and 11.2 kg on the three Mounjaro doses, compared with 5.7 kg on semaglutide 1 mg. These are averages from one trial, not a promise for any one person.

    What the Trial Does Not Tell You

    The trial compared semaglutide at 1 mg, while the Ozempic label now goes up to 2 mg. It also studied adults with diabetes only, so the right choice for you still depends on your health and your prescriber.

    Dose Steps Listed on Each Label

    Quoted from the FDA labels so the numbers make sense. These are each label's own schedule, not a recommendation or a plan for you.

    Mounjaro Steps

    The Mounjaro label starts at 2.5 mg once weekly. If more blood sugar control is needed, it increases in 2.5 mg steps after at least 4 weeks on the current dose, up to 15 mg for adults.

    Ozempic Steps

    The Ozempic injection label starts at 0.25 mg once weekly for 4 weeks, then 0.5 mg. If more control is needed, it lists 1 mg and then 2 mg, each after at least 4 weeks on the step before.

    Ozempic tablets have their own daily ladder of 1.5 mg, 4 mg and 9 mg on a separate label. The tablet label says its tablets are not swapped milligram for milligram with Rybelsus tablets.

    Why the Milligram Numbers Can't Be Compared

    Tirzepatide and semaglutide are different molecules, and milligram amounts of different molecules can't be compared. There is no conversion between the two, and your prescriber sets every step.

    Common Side Effects on Each Label

    Both sets of figures come from placebo-controlled trials in adults with type 2 diabetes. Mounjaro's column is the range across its doses; Ozempic's shows the two doses studied.

    Side effectMounjaroOzempic
    Nausea12-18% vs 4% placebo15.8% and 20.3% vs 6.1% placebo
    Diarrhea12-17% vs 9% placebo8.5% and 8.8% vs 1.9% placebo
    Vomiting5-9% vs 2% placebo5% and 9.2% vs 2.3% placebo
    Constipation6-7%5% and 3.1% vs 1.5% placebo

    Other Effects on the Lists

    The Mounjaro label also lists decreased appetite, indigestion and stomach pain among its common effects. The Ozempic label lists stomach pain and constipation among its most common effects.

    Why the Label Tables Differ

    Each label's numbers come from its own trials with different people and doses, so read each column against its own placebo rather than against the other.

    Full Breakdowns for Each Brand

    The GLP-1 side effects guide covers the full tables, why these effects happen and the warning signs to act on.

    The Boxed Warning and Other Shared Risks

    Both medicines share most of their serious warnings.

    Boxed Warning: Thyroid C-Cell Tumors

    Both labels carry a boxed warning because the active ingredient caused thyroid C-cell tumors in rodents, and it is unknown whether this happens in people. Neither should be used by anyone with a personal or family history of medullary thyroid carcinoma (MTC) or with multiple endocrine neoplasia syndrome type 2 (MEN 2). Report a lump or swelling in the neck, trouble swallowing, hoarseness or shortness of breath.

    Pancreatitis, Gallbladder and Kidneys

    Both labels list acute pancreatitis, gallbladder disease and kidney injury linked to fluid loss from vomiting or diarrhea. Severe stomach pain that does not go away needs prompt medical attention.

    Low Blood Sugar and Eye Changes

    Low blood sugar is more likely when either is used with insulin or a sulfonylurea. Both labels also mention diabetic eye complications in people with a history of retinopathy.

    Birth Control Pills and Procedures

    The Mounjaro label includes a note for people who use birth control pills, so ask your prescriber what it means for you. Both labels ask you to tell your care team about any planned surgery that uses anesthesia or deep sedation.

    Keep Either Medicine Organized in Pep AI

    After the prescriber decides, daily tracking is what matters.

    Quick Logging for Either Shot

    Pep AI logs a Mounjaro or Ozempic shot in a couple of taps, with its own schedule and step-ups. The body map shows where your recent shots went, so rotating sites gets easier. See the Mounjaro tracker and the Ozempic tracker.

    Shot-Day Reminders That Fit Your Week

    Pep AI reminds you on shot day, and your schedule stays the same week to week unless your prescriber changes it. On iPhone, home-screen widgets, a Lock Screen Live Activity and an Apple Watch app show what is due at a glance.

    Symptoms, Day by Day

    Pep AI's side-effect log has a built-in list of GLP-1 symptoms, plus your own, each rated for severity on the day you log it. Your dose history keeps its dates too, so you can check which days a step-up came before.

    Meals in the Same App

    Meals logged by photo scan, barcode, restaurant menu scan or search sit in the same app as your shots, with estimated protein and fiber up front. It becomes easier to see which foods sit well on harder days. More in the GLP-1 food tracker.

    Key takeaways

    • Mounjaro (tirzepatide) acts on GIP and GLP-1 receptors; Ozempic (semaglutide) acts on GLP-1.
    • Both are once-weekly injections for adults with type 2 diabetes; neither label lists weight reduction.
    • In SURPASS-2, all three Mounjaro doses lowered average HbA1c more than semaglutide 1 mg, and average weight loss was larger too.
    • Milligram amounts of different molecules can't be compared, and there is no conversion between them.
    • Which medicine and any switch are your prescriber's decision.

    Whatever your prescriber decides, keep the record.

    Doses, side effects, meals and weight for any GLP-1 brand, in one app. Pep AI is free to try on iPhone and Android: a free download with a 3-day free trial, then a subscription.

    Download on the App StoreGet it on Google Play

    Frequently asked questions

    Keep reading

    Sources

    1. Mounjaro (tirzepatide) prescribing information, Eli Lilly / FDA (revised 08/2026)
    2. Ozempic (semaglutide) injection prescribing information, Novo Nordisk / FDA (revised 05/2026)
    3. Rybelsus and Ozempic (semaglutide) tablets prescribing information, Novo Nordisk / FDA (revised 01/2026)
    4. Zepbound (tirzepatide) prescribing information and Medication Guide, Eli Lilly / FDA (revised 08/2026)
    5. Frías JP et al. Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes (SURPASS-2). N Engl J Med 2021;385:503-515

    This page compares FDA prescribing information and published trials for general information. It is not medical advice and does not tell you which medicine or dose to take; that decision belongs to you and your prescriber. Dose steps are quoted from each label's own schedule, not as a plan for you. Pep AI is not affiliated with Novo Nordisk or Eli Lilly, and brand names are trademarks of their owners. If a symptom is severe or worrying you, contact your healthcare provider. In an emergency, call 911.

    Published by the Pep AI team · Updated November 2026